Localized incompletely resected standard risk rhabdomyosarcoma
in children and adolescents: Results from the European
Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial

J 2024

Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial

MANDEVILLE, Henry C, Gianni BISOGNO, Veronique MINARD-COLIN, Rita ALAGGIO, Myriam BEN-ARUSH et. al.

Základní údaje

Originální název

Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial

Autoři

Vydání

Cancer, Hoboken, Wiley, 2024, 0008-543X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.100 v roce 2023

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/cncr.35497

UT WoS

001278087300001

Klíčová slova anglicky

alkylator chemotherapy; pediatric sarcoma; radiotherapy; rhabdomyosarcoma; surgical resection

Štítky

14110321, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 1. 2025 12:24, Mgr. Tereza Miškechová

Anotace

V originále

Background: The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS). Patients and Methods: Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m(2) ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m(2) ifosfamide) +/- radiotherapy. Delayed primary tumor excision was considered for IRS III tumors. The primary end points were event-free survival (EFS) and overall survival (OS). Results: From October 2005 to December 2016, 359 evaluable patients were recruited: orbit, 164 (45.7%); head and neck nonparameningeal, 77 (21.4%); and genitourinary non-bladder/prostate, 118 (32.9%). EFS and OS were 77.4% (95% confidence interval [CI], 72.5-81.6) and 93.5% (95% CI, 90.1-95.8), respectively. Lower dose alkylator chemotherapy and radiotherapy achieved 5-year OS of 93.7% but the difference with higher dose alkylator chemotherapy +/- radiotherapy was not significant (p = 0.8003). Adjuvant radiotherapy improved EFS with 5-year estimates of 84.7% versus 65.2% for nonirradiated (p < .0001), but not OS (p = .9298). Omitting radiotherapy for orbital tumors reduced OS (5-year was 87.1% vs. 97.3% for irradiated, p = .0257). Following R0 resection (n = 60), radiotherapy did not significantly improve EFS or OS. Conclusions: Radiotherapy for local tumor control allows for reduction of cumulative dose of alkylators in EpSSG standard risk subgroup C RMS patients. The omission of radiotherapy did not affect OS in all patients except those with orbital RMS and was associated with inferior EFS.

Citovat

MANDEVILLE, Henry C, Gianni BISOGNO, Veronique MINARD-COLIN, Rita ALAGGIO, Myriam BEN-ARUSH, Cyrus CHARGARI, Beatrice COPPADORO, Ross CRAIGIE, Christine DEVALCK, Sima FERMAN, Andrea FERRARI, Heidi GLOSLI, Raquel Hladun ALVARO, Marinka HOL, Peter MÚDRY, Daniel ORBACH, Monica Ramos ALBIAC, Johannes H M MERKS a Meriel E M JENNEY. Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial. Cancer. Hoboken: Wiley, 2024, roč. 130, č. 23, s. 4071-4084. ISSN 0008-543X. Dostupné z: https://dx.doi.org/10.1002/cncr.35497.

@article{2429677,
   author = {Mandeville, Henry C and Bisogno, Gianni and MinardandColin, Veronique and Alaggio, Rita and BenandArush, Myriam and Chargari, Cyrus and Coppadoro, Beatrice and Craigie, Ross and Devalck, Christine and Ferman, Sima and Ferrari, Andrea and Glosli, Heidi and Alvaro, Raquel Hladun and Hol, Marinka and Múdry, Peter and Orbach, Daniel and Albiac, Monica Ramos and Merks, Johannes H M and Jenney, Meriel E M},
   article_location = {Hoboken},
   article_number = {23},
   doi = {http://dx.doi.org/10.1002/cncr.35497},
   keywords = {alkylator chemotherapy; pediatric sarcoma; radiotherapy; rhabdomyosarcoma; surgical resection},
   language = {eng},
   issn = {0008-543X},
   journal = {Cancer},
   title = {Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial},
   url = {https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35497},
   volume = {130},
   year = {2024}
}

TY  - JOUR
ID  - 2429677
AU  - Mandeville, Henry C - Bisogno, Gianni - Minard-Colin, Veronique - Alaggio, Rita - Ben-Arush, Myriam - Chargari, Cyrus - Coppadoro, Beatrice - Craigie, Ross - Devalck, Christine - Ferman, Sima - Ferrari, Andrea - Glosli, Heidi - Alvaro, Raquel Hladun - Hol, Marinka - Múdry, Peter - Orbach, Daniel - Albiac, Monica Ramos - Merks, Johannes H M - Jenney, Meriel E M
PY  - 2024
TI  - Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial
JF  - Cancer
VL  - 130
IS  - 23
SP  - 4071-4084
EP  - 4071-4084
PB  - Wiley
SN  - 0008543X
KW  - alkylator chemotherapy
KW  - pediatric sarcoma
KW  - radiotherapy
KW  - rhabdomyosarcoma
KW  - surgical resection
UR  - https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35497
N2  - Background: The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS). Patients and Methods: Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m(2) ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m(2) ifosfamide) +/- radiotherapy. Delayed primary tumor excision was considered for IRS III tumors. The primary end points were event-free survival (EFS) and overall survival (OS). Results: From October 2005 to December 2016, 359 evaluable patients were recruited: orbit, 164 (45.7%); head and neck nonparameningeal, 77 (21.4%); and genitourinary non-bladder/prostate, 118 (32.9%). EFS and OS were 77.4% (95% confidence interval [CI], 72.5-81.6) and 93.5% (95% CI, 90.1-95.8), respectively. Lower dose alkylator chemotherapy and radiotherapy achieved 5-year OS of 93.7% but the difference with higher dose alkylator chemotherapy +/- radiotherapy was not significant (p = 0.8003). Adjuvant radiotherapy improved EFS with 5-year estimates of 84.7% versus 65.2% for nonirradiated (p < .0001), but not OS (p = .9298). Omitting radiotherapy for orbital tumors reduced OS (5-year was 87.1% vs. 97.3% for irradiated, p = .0257). Following R0 resection (n = 60), radiotherapy did not significantly improve EFS or OS. Conclusions: Radiotherapy for local tumor control allows for reduction of cumulative dose of alkylators in EpSSG standard risk subgroup C RMS patients. The omission of radiotherapy did not affect OS in all patients except those with orbital RMS and was associated with inferior EFS.
ER  -

MANDEVILLE, Henry C, Gianni BISOGNO, Veronique MINARD-COLIN, Rita ALAGGIO, Myriam BEN-ARUSH, Cyrus CHARGARI, Beatrice COPPADORO, Ross CRAIGIE, Christine DEVALCK, Sima FERMAN, Andrea FERRARI, Heidi GLOSLI, Raquel Hladun ALVARO, Marinka HOL, Peter MÚDRY, Daniel ORBACH, Monica Ramos ALBIAC, Johannes H M MERKS a Meriel E M JENNEY. Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial. \textit{Cancer}. Hoboken: Wiley, 2024, roč.~130, č.~23, s.~4071-4084. ISSN~0008-543X. Dostupné z: https://dx.doi.org/10.1002/cncr.35497.

Přehled o publikaci